154 related articles for article (PubMed ID: 12521611)
1. Severe sepsis.
Bernard G
Am J Surg; 2002 Dec; 184(6A Suppl):S3-4. PubMed ID: 12521611
[No Abstract] [Full Text] [Related]
2. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
Dhainaut JF
Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
[No Abstract] [Full Text] [Related]
3. [PROWESS--milestone in lowering sepsis mortality].
Reinhart K
Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
[No Abstract] [Full Text] [Related]
4. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
Maki DG
Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
[No Abstract] [Full Text] [Related]
5. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee.
Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610
[No Abstract] [Full Text] [Related]
6. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
Haas I
Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
[No Abstract] [Full Text] [Related]
7. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
Powers J; Jacobi J
Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
[No Abstract] [Full Text] [Related]
8. Breakthrough found in treatment of severe sepsis.
Clin Resour Manag; 2001 Jul; 2(7):107-9. PubMed ID: 11482248
[TBL] [Abstract][Full Text] [Related]
9. Risk-benefit analysis for drotrecogin alfa (activated).
Schein RM; Kinasewitz GT
Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human activated protein C for severe sepsis.
Ott A; Verbrugh HA
N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463023
[No Abstract] [Full Text] [Related]
11. Drotrecogin alfa (activated) for severe sepsis.
Maglio D
Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
[No Abstract] [Full Text] [Related]
12. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
Sollet JP; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human activated protein C for severe sepsis.
O'Connor PE
N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463024
[No Abstract] [Full Text] [Related]
14. Recombinant human activated protein C for severe sepsis.
Kapur S; Kupfer Y; Tessler S
N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
[No Abstract] [Full Text] [Related]
15. Recombinant human activated protein C for severe sepsis.
Greisman SE; Johnston CA; Gosnell MS
N Engl J Med; 2001 Jul; 345(3):219; author reply 220-1. PubMed ID: 11463022
[No Abstract] [Full Text] [Related]
16. New thoughts on sepsis: the unifier of critical care.
Schulman CS; Hare K
Dimens Crit Care Nurs; 2003; 22(1):20-30. PubMed ID: 12548098
[TBL] [Abstract][Full Text] [Related]
17. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
Morris PE; Light RB; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
[TBL] [Abstract][Full Text] [Related]
18. [Protein C--a new opening in the treatment of sepsis syndrome].
Petäjä J; Heikinheimo M
Duodecim; 2002; 118(12):1217-9. PubMed ID: 12239812
[No Abstract] [Full Text] [Related]
19. Management of patients with severe sepsis, treated by drotrecogin alfa (activated).
Laterre PF; Heiselman D
Am J Surg; 2002 Dec; 184(6A Suppl):S39-46. PubMed ID: 12521616
[TBL] [Abstract][Full Text] [Related]
20. Activated protein C in severe sepsis.
Bradley C
Intensive Crit Care Nurs; 2001 Jun; 17(3):177-8. PubMed ID: 11868688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
